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Abstract
Introduction: Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ICS) are costly. They are
recommended in severe or very severe chronic obstructive pulmonary disease (COPD). They should not be
prescribed in mild or moderate disease. In COPD ICS are associated with side-effects including risk of pneumonia.
We quantified appropriateness of prescribing and examined the risks and costs associated with overuse.
Methods: Data were extracted from the electronic and paper records of 41 London general practices (population
310,775) including spirometry, medications and exacerbations. We classified severity, assessed appropriateness of
prescribing using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for 2009, and
performed a sensitivity analysis using the broader recommendations of the 2011 revision.
Results: 3537 patients had a diagnosis of COPD. Spirometry was recorded for 2458(69%). 709(29%) did not meet
GOLD criteria. 1749(49%) with confirmed COPD were analysed: 8.6% under-treated, 38% over-treated. Over-
prescription of ICS in GOLD stage I or II (n=403, 38%) and in GOLD III or IV without exacerbations (n=231, 33.6%)
was common. An estimated 12 cases (95%CI 7-19) annually of serious pneumonia were likely among 897
inappropriately treated. 535 cases of overtreatment involved LABA+ICS with a mean per patient cost of £553.56/year
(€650.03). Using the broader indications for ICS in the 2011 revised GOLD guideline 25% were still classified as
over-treated. The estimated risk of 15 cases of pneumonia (95%CI 8-22) in 1074 patients currently receiving ICS
would rise by 20% to 18 (95%CI 9.8-26.7) in 1305 patients prescribed ICS if all with GOLD grade 3 and 4 received
LABA+ICS.
Conclusion: Over-prescription of ICS in confirmed COPD was widespread with considerable potential for harm. In
COPD where treatment is often escalated in the hope of easing the burden of disease clinicians should consider both
the risks and benefits of treatment and the costs where the benefits are unproven.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) places a
significant burden on health services. In the UK, as in many
countries, most COPD management takes place in primary
care[1-3]. However, the variable quality of spirometry in primary
care and the appropriateness of COPD prescribing have been
questioned[2,4,5]. Reflecting the hope that inhaled
corticosteroids (ICS) may improve outcomes, particularly in
severe disease[6], high rates of ICS prescribing for COPD have
been reported in many countries, raising concerns about over-
prescribing[1-3,7].
The effectiveness of ICS (normally prescribed in combination
with long-acting beta-agonists (LABA)) in the prevention of
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exacerbations (in frequent exacerbators with more severe
COPD) is established: their role in ameliorating COPD
symptoms is unproven. Early hopes that they would improve
quality of life (QoL) have not been confirmed[8]. Although
statistically significant improvements in QoL scores have been
shown in some large trials of combined ICS and LABA, none
has shown an improvement reaching the minimal clinically
important difference (MCID) of the instrument used[9-16]. In
only three trials has the upper limit of the 95% confidence
interval of the improvement in intervention group patients
reached the MCID[11,14,15]. Disappointed in the lack of
evidence [6,8] Sin and Man in 2010 made the questionable
suggestion that “A more plausible (and simple) explanation (for
the high worldwide sales of combined ICS/LABA) is that
clinicians (and patients) use ICS-based therapy for COPD
because they work”.[8] Discussion of the role of ICS in
symptom management of COPD was notable by its absence in
the recent Lancet review by Rabe and Wedzicha[17]. There is
no evidence to support the use of ICS as mono-therapy or in
combination with LAMA at any severity level of COPD.
Guidelines have adopted different positions in the face of
equivocal evidence supporting ICS use for COPD symptoms.
The UK National Institute for Health and Clinical Excellence
(NICE) revised its COPD guideline in 2010 and included the
advice that “in people with stable COPD and an FEV1 ≥ 50%
predicted who remain breathless consider LABA and ICS in a
combination inhaler”.[18] More cautiously the American College
of Physicians’ clinical guideline on COPD states: “the evidence
is insufficient to support a strong recommendation for the broad
use of combination therapy, and clinicians will need to weigh
the potential benefits and harms on a case by case basis.” In
contrast, the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guideline 2009 (current at the time of our data
collection) recommended ICS to prevent exacerbations in
patients with severe disease and a history of frequent
exacerbations. The 2011 revised GOLD guideline now explicitly
regards all patients with severe/very severe COPD as at risk of
exacerbations and thus eligible for treatment with ICS/LABA
regardless of their past exacerbation status[19]. Classification
of severity was changed from four stages (I-IV) to four grades
(1-4), using the same spirometry thresholds, but adding
symptom-based estimates of severity. The guideline now
recommends LABA+ICS for all patients in grades 3-4 on the
basis that their risk of exacerbation is higher. It acknowledges
the risk of pneumonia in COPD patients prescribed ICS but
does not quantify this risk. Until the TORCH trial (2007)
highlighted the risk of pneumonia, ICS were generally
considered safe from serious side effects. Since then evidence
of the risk of pneumonia and fractures in people with COPD on
ICS has been growing[13,20-22]. Singh et al estimated the
relative risk of severe pneumonia in COPD treated with
combined LABA+ICS when compared to LABA alone to lie
between 1.46 (CI 1.26-1.69) and 1.56 (CI 1.4-1.74). NICE
estimated the annual number needed to harm (NNH) for severe
pneumonia as a consequence of ICS use in COPD as 60 to 72
people[18,22]. The total cost of combined LABA+ICS in the UK
is more than any other drug. In 2010, £497,665,559
(€584,469,239) was spent on combination inhalers in England,
a 7% increase on the previous year (NHS Business Authority,
Freedom of Information Request, 110407 Booth 515237, 7
April 2011). Much of this ICS/LABA prescribing is for COPD
where the equivocal evidence, diverse interpretations, and
changing recommendations in guidelines could lead to
considerable confusion and inappropriate prescribing. This
study aimed to examine at patient level, in a population of more
than 300,000, the rate of prescribing of ICS for COPD, the
adherence of that prescribing to international guidelines, and its
impact on risk and cost in general practice.
Materials and Method
Ethics statement.  Ethical approval was obtained from the
South East Research Ethics Committee, REC reference 09/
H1102/19. All patient data were anonymised prior to provision.
No patient identifiable data were retained by the research
team.
We stratified 98 practices in the London boroughs of
Lambeth and Southwark by list size and by socio-economic
status using the 2007 Index of Multiple Deprivation (IMD) score
derived from each practice’s postcode. IMD score is based on
national census and local authority data, and reflects
deprivation specific to a geographical area[23]. IMD scores in
2007 ranged nationally from 0 (least deprived) to 86 (most
deprived). We invited 51 practices at random to participate.
Practice characteristics were obtained from the NHS
Information Centre Quality and Outcomes Framework
database[24]. An administrator, employed by practices but
trained by the research team, obtained data on all patients on
the practice COPD registers using electronic and hand
searches of records between December 2009 and November
2010. Data were provided in anonymised form. Participating
practices received service support costs from The UK Primary
Care Research Network.
We collected demographic information (age, gender,
ethnicity and postcode) and clinical data related to COPD
diagnosis and management (including spirometry, inhaled and
oral drug prescriptions in the last year, smoking history,
occurrence of COPD exacerbations, hospital admissions,
prescription of oral prednisolone for COPD in the last two
years, and data on co-morbidities). We used patients’
postcodes to calculate patients’ IMD scores.
Spirometry.  Spirometry was accepted if FEV1 (forced
expiratory volume in one second), FVC (forced vital capacity),
height, date of birth and gender were available. These enabled
GOLD severity grading. Biologically “implausible” values of
FEV1 or FVC were excluded. Patients whose spirometry met
criteria for a diagnosis of COPD (FEV1/FVC ratio <70%) were
categorised into severity stages according to GOLD
classification using FEV1 and history of exacerbations (Table
1). We accepted at least one exacerbation requiring oral
steroids or hospital admission for COPD as evidence of risk of
repeated exacerbations. We did this for three reasons:
prescribing decisions might have taken into account similar
events not explicitly noted in the medical record; LABA+ICS
prescriptions may have been initiated in hospital clinics or
during hospital admissions without recording the indication; and
retrospective identification of the date of introduction of ICS
Overtreatment of COPD with Inhaled Corticosteroids
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and the frequency of exacerbation or admission in the
preceeding three years was complex. This decision means we
may have underestimated the over-prescribing of ICS.
Characteristics of patients with spirometry-confirmed COPD
were compared using logistic regression to those whose COPD
was not confirmed. Allowance for clustering within practices
was made using the Huber-White robust variance
estimator[25]. Quality of treatment was only analysed in
patients with spirometry confirmed diagnosis of COPD. Data
were analysed using STATA Version 11 (Statacorp, Texas).
Drug management and analysis
Inhaled drug treatment was assessed against GOLD (2009
update) according to the patient’s severity (Table 1)[26].
Patients were classified as under-treated, appropriately treated
or over-treated for GOLD stage. In the absence of reliable
symptom data, we accepted absence of treatment as
appropriate in patients with no recorded exacerbations at any
severity stage although we recognised that this may have
represented under-treatment of symptoms. In line with asthma
guidelines ICS were considered appropriate in patients with
asthma, or a history of asthma, irrespective of their GOLD
stage. Assessment of possible under-treatment with lower dose
ICS (beclomethasone or budesonide in single drug inhalers) in
severe or very severe COPD with exacerbations was complex
due to the difficulty in counting total doses of these steroids
prescribed over the study period. As less than 2% of these
patients were on these lower dose steroid inhalers there may
have been minor under-estimation of under-treatment in these
patients.
Predictors of over-treatment were sought using univariate
and multiple logistic regression using the Huber-White robust
variance estimator to account for clustering[25].
Table 1. Treatments considered acceptable at each GOLD
stage (2009 update).
GOLD STAGE FEV1 % predicted
No
treatment*
SAMA/
SABA**
LAMA/
LABA ICS***
I (mild) ≥80% Yes Yes No No
II (moderate) 50%≤FEV1<80% Yes Yes Yes No
III (severe) 30%≤FEV1<50% Yes Yes Yes No
IV (very severe) <30% Yes Yes Yes No
III or IV with
exacerbations - No Yes Yes Yes
* Without access to current symptom data (eg breathlessness) absence of
treatment was considered appropriate in patients at all severity stages provided
they had no exacerbations.
** SAMA/SABA Short-acting muscarinic or beta2-agonist; LAMA/LABA Long-acting
muscarinic or beta2-agonist; ICS Inhaled cortico-steroid
*** Treatment with LABA + ICS or ICS alone was acceptable for any patients with a
diagnosis of asthma or history of asthma
doi: 10.1371/journal.pone.0075221.t001
Risk of pneumonia
Risk of pneumonia was assessed in all patients treated with
ICS, and in those judged to be receiving ICS inappropriately.
We used estimates of the relative risk of pneumonia associated
with ICS treatment from the meta-analysis in the NICE 2010
guideline examining LABA+ICS versus LABA[18]. NICE
estimated the relative risk (RR) for serious pneumonia in
COPD as 1.46 (95%CI 1.26-1.69) for treatment with LABA+ICS
compared to LABA[18]. A baseline event rate for serious
pneumonia of 30 per 1000 person-years was used, as reported
by Singh et al.[27] The annual number needed to harm (NNH)
based on these figures was 72.4 (95% CI 48.3-128.2).
Cost analysis
Costs of prescribed respiratory drugs in England in 2010
were provided by the NHS Business Services Authority in
response to a Freedom of Information request (NHS Business
Authority, Freedom of Information Request, 110407 Booth
515237, 7 April 2011). We obtained costs associated with
prescription of all forms of LABA+ICS for England, London, and
Lambeth and Southwark Primary Care Trusts (Primary Care
Trusts are freestanding NHS bodies responsible for delivering
health care and health improvements in their locality). We also
obtained costs for the ten most expensive prescribed drugs by
net ingredient cost for the same geographical areas with which
we could compare the relative cost of respiratory drugs. Mean
costs of inhaled respiratory drugs were estimated by applying
the average monthly cost of the dose recommended in the
British National Formulary (BNF) in a CFC-free single or
combination preparation for each drug e.g. for ICS in a
combination inhaler the mean cost of one month’s treatment
with salmeterol and fluticasone (50mcg/500mcg twice daily via
Evohaler® or Accuhaler®), and formoterol and budesonide
(12mcg/400mcg twice daily via Turbohaler®) was taken[28].
Ranges for costs were calculated using the lowest and highest
prices of the different available drugs.
Sensitivity analysis
In 2011, 9 months after data collection was completed, the
GOLD guideline was revised to incorporate broader indications
for ICS prescribing. To evaluate the impact of the revised
GOLD guideline on the assessment of rates of under-treatment
and over-treatment, the predictors of overtreatment, and the
risk of pneumonia, we carried out a sensitivity analysis
replacing the 2009 GOLD guideline treatment definitions (Table
1) with the revised GOLD 2011 definitions (Supplementary
information – Table S1)[19]. The revised analysis is presented
in supporting information labeled Tables S1-S4 and Figure S1.
Results
Practice characteristics
Data were obtained from 41 (80%) general practices serving
a population of 310,775. There were no significant differences
between the 41 participating and 10 non-participating practices
in size, demographic and quality indicator characteristics
(based on NHS Information Centre Quality and Outcomes
Overtreatment of COPD with Inhaled Corticosteroids
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Framework), and prevalence of COPD. 3537 (1.14%) patients
with a diagnosis of COPD were identified. After removing
records with incomplete or implausible spirometry, data from
2458 patients were used in the analysis of treatment
appropriateness (Figure 1).
The characteristics of participating practices are shown in
Table 2.
Patient characteristics
Patients with spirometry-confirmed COPD were compared to
those whose COPD was not confirmed (Table 3). The average
IMD score in our study (and in the local population) lay within
the most deprived quintile of the country. Patients with
spirometry-confirmed COPD were older, had lower FEV1
(where available), fewer co-morbidities, and were more likely to
be ex- or current smokers. Ethnicity data were available for
54.8%. 80.3% were white and 8.5% were black compared to
62.7% white and 25.83% black in the local population[29,30].
Figure 1.  Identification of subjects and categorization by
diagnosis and severity (GOLD stage) in 41 practices.  
doi: 10.1371/journal.pone.0075221.g001
Diagnosis and disease severity
709 (28.8%) patients with complete spirometry records did
not meet the COPD diagnostic criterion of an FEV1/FVC ratio
<70%. GOLD stages of those with spirometry are shown in
Figure 1.
Exacerbations
26% of patients with spirometry-confirmed COPD had at
least one course of high-dose oral steroids (≥20mg
prednisolone daily) in the previous two years, and 8.8% had
been admitted to hospital with an exacerbation. Patients with
confirmed COPD were more likely to have had oral steroids,
had an exacerbation, been admitted to hospital with COPD,
and have received treatment with SABA, SAMA or LAMA than
patients without spirometric confirmation.
Drug treatment
Inhaled medications were prescribed in line with 2009 GOLD
guidelines for 59.8% patients with confirmed COPD. 8.6% were
under-treated and 37.7% appeared to be over-treated for their
GOLD stage (table 4). 106 patients were classed as both
under- and over-treated as they were over-treated with ICS but
under-treated without SABA and/or LABA. Over-treatment was
more likely in mild patients and under-treatment increased with
severity (Figure 2). Of the 659 patients classed as over-treated
634 (96.2%) were over-treated with ICS. Among the 469
patients without spirometry-confirmed COPD or a diagnosis of
asthma, 238 (50.7%) were receiving ICS.
Table 2. Practice characteristics.
 Mean SD
Practice list size (n) 7998 4766
Index of Multiple Deprivation Score (IMD) 2007 33.1 9.9
COPD QOF* points awarded 2009/10 (% of available total)** 92.9% 15.6%
Overall QOF* points awarded 2009/10 (% of available
total)*** 92.0% 4.9%
Practice prevalence of COPD 1.03% 0.44%
Proportion of list >45 years (%) 28.6% 5.3%
Sex (% male) 50.9% 3.4%
Training practices† (%) 12 (31.58%) -
Proportions of patients treated in line with GOLD‡ (%)
(practice means and SD) 58.1% 19.4%
Proportions of patients under-treated according to GOLD‡
(%) (practice means and SD) 11.9% 8.9%
Proportions of patients over-treated according to GOLD‡
(%) (practice means and SD) 39.2% 19.0%
* Quality and Outcomes Framework element of NHS GP contract
** National average: 95.8%, SD 12.6%
*** National average: 93.7%, 6.4 SD %
† Practice in which a GP trainer and the whole practice have been approved for the
purposes of postgraduate training of general practitioners
‡ GOLD guideline 2009 update
doi: 10.1371/journal.pone.0075221.t002
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Table 3. Patient characteristics and treatment.
 
All patients
(n=3537)
Patients with
COPD
confirmed by
spirometry
(n=1749)
Characteristics of
patients with COPD
confirmed by
spirometry (n=1749)
compared to those
whose spirometry did
not meet criteria for
COPD (FEV1/FVC≥0.7)
(n=709)
   OR 95% CI
Gender (Male) 1807(51.23%) 944 (53.97%) 1.14 0.86-1.52
Age at data
collection (years) 69.8 (12.0) 68.3 (10.8) 1.02 1.01-1.03†
Index of Multiple
Deprivation (IMD)* 35.5 (9.2) 35.9 (8.8) 0.1 0.96-1.03
FEV1 (l) - 1.39 (0.58) 0.27 0.22-0.33†
FEV1 (% predicted) - 56.9%(20.2%) 0.96 0.95-0.96†
Number of co-
morbidities 1.4 (1.2) 1.32 (1.1) 0.86 0.81-0.92†
Diagnosis of
depression (%) 709 (21.3%) 311 (19.0%) 0.76 0.62-0.93†
Never-smoker** 320 (9.0%) 113 (6.5%) 0.53 0.32-0.87†
Ex-Smoker 1473(41.8%) 755 (43.2%) 1.23 1.01-1.5†
Current smoker 1160(32.9%) 606 (34.7%) 1.10 0.92-1.33
Oral steroids in the
previous 2 years 866 (24.6%) 455 (26.0%) 1.44 1.19-1.74†
Hospital admission
for COPD in the
previous 2 years
295 (8.47%) 153 (8.8%) 1.48 1.11-1.99†
Exacerbation in the
previous 2 years 456 (12.9%) 235 (13.4%) 1.44 1.14-1.82†
Long-term oxygen
therapy 131 (3.7%) 60 (3.4%) 1.54 0.88-2.68
Treatment with
SABA
2551
(72.3%) 1338 (76.5%) 1.56 1.29-1.89†
Treatment with
SAMA 518 (14.7%) 290 (16.6%) 1.52 1.10-2.09†
Treatment with
LABA 623 (17.7%) 351 (20.1%) 1.21 0.92-1.58
Treatment with
LAMA
1359
(38.5%) 791 (45.2%) 2.07 1.63-2.64†
Treatment with ICS 1200(34.0%) 628 (35.9%) 0.99 0.70-1.4
Treatment with
LABA + ICS
combined
1333
(37.8%) 705 (40.3%) 1.18 0.93-1.49
Treatment with ICS
(combination or
single)
2076
(58.9%)
1074
(61.41%) 1.12 0.89-1.41
Predictors of overtreatment
Predictors of over-treatment according to GOLD stage were
sought using univariate and multivariate analysis (Table 5).
Variables with the strongest univariate associations with over-
treatment (Table 5) were MRC Dyspnoea Score (over-
treatment less likely with more severe MRC score), GOLD
stage (over-treatment less likely in GOLD stage III or IV), and
exacerbations or hospital admissions for COPD in the previous
two years (over-treatment less likely in patients who reported
an exacerbation requiring oral steroids or a hospital admission
for COPD). Predictors of over-treatment in the multivariate
analysis were an exacerbation of COPD in the last two years,
IMD score and MRC score.
Risk of pneumonia
Using the estimated NNH of 72.4, 29 cases (95%CI 16-43) of
serious pneumonia were likely to have been observed among
the 2076 taking ICS. Twelve cases (95% CI 7-19) were likely to
have occurred in the 897 patients with or without confirmed
COPD whom we assessed as being inappropriately treated
with ICS.
Table 3 (continued).
SABA=short-acting beta2-agonist; SAMA = short-acting muscarinic antagonist;
LABA = long-acting beta2-agonist; LAMA = long-acting muscarinic antagonist; ICS
= inhaled corticosteroid
*. Mean national IMD for 2007 was 21.7 (range 0.4-85.5); mean IMD for Lambeth
and Southwark was 34.2 (range 7.1-58.9)
**. Smoking status data were missing in 17% of patients
†. Indicates a significant difference
doi: 10.1371/journal.pone.0075221.t003
Table 4. Patients with spirometry-confirmed COPD:
Treatment by GOLD stage (2009 update).
GOLD† stage
Treated in line with
GOLD†
recommendations
(%)
Under-treated
according to GOLD†
recommendations
(%)
Over-treated
according to GOLD†
recommendations
(%)
I - mild
(n=203) 109 (53.7%) 0 (0%) 94 (46.3%)
II - moderate
(n=859) 509 (61.1%) 42 (4.89%) 334 (38.9%)
III - severe
(n=534)* 326 (61.1%) 86 (16.1%) 187 (35.0%)
IV - very
severe
(n=153)
102 (66.7%) 22 (14.38%) 44 (28.8%)
Total
(n=1749) 1046 (59.8%) 150 (8.6%) 659 (37.68%)
*. Some patients were classed as both under and over-treated
†. GOLD 2009 update
doi: 10.1371/journal.pone.0075221.t004
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Cost of overtreatment
The mean monthly price for combined LABA+ICS at the time
of the study was £46.13(€54.16) and for single preparation ICS
inhalers was £12.76(€14.98). Of the 659 (37.68%) with
confirmed COPD over-treated in this study 397 were
prescribed combination inhalers and the remainder single
preparation ICS. Based on the mean drug cost, the estimated
cost of over-prescribing ICS in these patients was
£21,657(€25,425) per month, or £259,881(€305,102) per year
(range per year: £195,023-£357,530)(€ 228,933-€ 419,696). In
the 709 patients in whom spirometry criteria for COPD were not
met and who did not have a diagnosis of asthma 238 (33.6%)
were receiving ICS (138 on combination inhaler and 100 on
single preparation). The estimated cost of prescribing ICS in
these patients each year was £91,244(€107,119)(range per
year: £68,108(€79,968)-£125,244(€147,078)).
If we assume that the severity and prescribing patterns of the
patients whose treatment appropriateness we were unable to
analyse due to incomplete spirometry data were the same as
those included in the study, the overall cost of overprescribing
would have been £505,260(€593,275) per year in the 41
practices (£12,323(€14,470) per practice).
Sensitivity analysis using the 2011 changes in the
GOLD guideline
The results of the sensitivity analysis which repeated all the
analyses are given in the attached supporting information,
Tables S1-S4. As a result of the application of the 2011 GOLD
Guidelines 231 severe/very severe COPD patients (GOLD
Stages III and IV) originally classified as over-treated (they
were taking inhaled corticosteroids and had not had an
exacerbation in the previous year) were reclassified as
appropriately treated (Supporting information - Table S1). This
would reduce the overall proportion of over-treated patients
among those with spirometry confirmed COPD from 38% to
24% (Supporting information – Table S3), and reduce the
practice mean proportion of patients over-treated to 17.1%
(Supporting information –Table S2). 203 severe/very severe
COPD patients (GOLD Stages III and IV) originally classified as
appropriately or under-treated because they had not had
inhaled corticosteroids were reclassified as under-treated.
Overtreatment of COPD was more likely in patients in GOLD
grade 1 compared to GOLD grade 2 (in which overtreatment
with SABA, LAMA, and LABA was no longer possible
according to GOLD 2011 revision) when controlling for
exacerbations, hospitalisation, MRC score, IMD score, smoking
history, and other co-morbidities, (multiple logistic regression -
OR 1.5, 95% CI 1.06-2.2; n=794) (Supplementary information -
Table S4). No other variables were predictive of overtreatment
in multivariate analysis. If all patients with GOLD grade 3 and 4
received LABA+ICS the estimated cases of pneumonia would
rise by 20% from 15 (95% CI 8-22) cases in the 1074 patients
with confirmed COPD currently receiving ICS to 18 (95% CI
9.8-26.7) cases each year in the 1305 patients who would
qualify for ICS according to the updated guidelines
Discussion
Over-treatment of COPD with inhaled corticosteroids was
widespread in this large study of COPD management. Of
patients who had a diagnosis of COPD confirmed by
spirometry, 38% were over-treated according to the GOLD
guidelines current at the time of prescribing. Excluding people
with asthma, in 96% of these cases over-treatment was with
Figure 2.  Proportion of patients with spirometric confirmation of diagnosis of COPD in each treatment classification by
GOLD stage.  
doi: 10.1371/journal.pone.0075221.g002
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ICS, resulting in an estimated 12 additional cases of severe
pneumonia every year[18]. Under-treatment was seen in
approximately 9% of patients, though this may be an
underestimate due to the absence of information on current
symptoms such as breathlessness, the only treatment
indication in mild and moderate COPD.
Table 5. Relationship between overtreatment and patient
characteristics in patients with a spirometry confirmed
diagnosis of COPD: univariate and multiple logistic
regression (using Huber-White robust variance estimator to
allow for clustering). (GOLD 2009 update).
Variable Number overtreated (%)OR (95% CI)
Age(years) 659 (38%) 1.01 (1.00-1.01)
Gender   
Female 299 (37%) 1.0
Male 360 (38%) 1.04 (0.86-1.27)
Index of Multiple Deprivation Score 659 (38%) 1.02 (1.01-1.03)
Smoking status   
Never smoker 40 (35%) 1.0
Ex-smoker 307 (41%) 1.25 (0.81-1.93)
Smoker 240 (40%) 1.2 (0.83-1.72)
GOLD Stage   
Stage I or II (mild to moderate) 428 (40%) 1.0
Stage III or IV (severe or very severe) 231 (34%) 0.75 (0.59-0.95)
MRC Dyspnoea Score   
1-2 201 (37%) 1.0
3 184 (47%) 1.53 (1.17-2.00)
4 116 (42%) 1.22 (0.90-1.64)
5 28 (42%) 1.25 (0.70-2.35)
Depression   
No 529 (40%) 1.0
Yes 120 (39%) 0.94 (0.74-1.20)
Exacerbation for COPD in <2 years   
No 604 (40%) 1.0
Yes 55 (23%) 0.46 (0.3-0.71)
Hospital Admission for COPD in <2
years   
No 625 (39%) 1.0
Yes 34 (22%) 0.44 (0.3-0.66)
Number of co-morbidities   
0 167 (38%) 1.0
1-2 378 (37%) 0.95 (0.71-1.28)
≥3 114 (42%) 1.19 (0.81-1.76)
Multiple Logistic Regression*   
MRC Dyspnoea Score  
1-2 1.0
3 1.66 (1.23-2.22)
4 1.44 (1.04-2.00)
5 2.08 (1.02-4.23)
COPD exacerbation in the last 2 years 0.35 (0.18-0.68)
Index of Multiple Deprivation score 1.02 (1.01-1.03)
*. Controlling for age, gender and GOLD stage. Pseudo R2 0.0294. Describes how
well (2.9%) the model performs when compared to a perfect prediction model
doi: 10.1371/journal.pone.0075221.t005
We estimated the annual cost of over-prescribing in this
study population to be £505,260 (€593,373) based on mean
prices for ICS[28]. If similar levels of over-prescribing were
seen throughout England the unnecessary cost would have
been about £102million (€119.8million) per year; this equates
to more than a fifth of actual spending on combination inhalers
in the year of the study.
The 2011 revision of the GOLD guidelines changed
retrospectively how these data might be interpreted now.
Estimates of overtreatment would fall from 38% to 24% and the
annual cost in England of this over-treatment would be £67
million (€79 million). Appropriate treatment would rise from
60% to 68% a smaller difference because some of those
patients who were over-treated with ICS were also under-
treated by not having had long-acting bronchodilators
prescribed. If the revised guideline prescribing indications were
adhered to consistently, the estimate of the risk of pneumonia
in COPD patients as a result of ICS prescribing would rise by
20%, raising important issues about the balance of risks and
benefits especially in patients with severe and very severe
COPD.
Limitations and strengths
A key issue in this study is the accuracy, completeness, and
reliability of routinely collected data extracted from primary care
records. All participating practices used computerised
prescribing so the prescription recorded was almost certainly
the prescription issued, although patients may not have
presented every prescription at a chemist, nor used the drug
that had been dispensed.
Spirometry results are essential to clinical treatment
decisions in COPD and should be recorded in the patient’s
record. The 2009 GOLD indications for prescribing ICS, which
were based on GOLD stage (% predicted FEV1) together with
history of exacerbations, have been revised and are now based
mainly on spirometry results in the 2011 GOLD update.
Bronchodilator prescribing is more difficult to judge because
objective recording of symptom status, the main indication, is
inconsistent[31]. We erred on the side of the prescriber
assuming absence of symptom recording meant absence of
symptoms and that bronchodilator treatment was not indicated.
This may have resulted in an underestimate of under-
prescribing. We may also have under-estimated over-
prescribing according to 2009 GOLD by defining the indication
for ICS in severe and very severe COPD as one exacerbation
requiring oral steroids or admission rather than three
exacerbations in the three years. This indication was removed
in the 2011 GOLD guidelines.
Participating practices were recruited from two adjacent
localities. However, participating practices were stratified by
size and socio-economic deprivation and randomly invited.
They served 62% of the population in the two study boroughs.
We found no differences between participating and non-
participating practices. The prescribing rates for combination
inhalers in these two boroughs were similar to national rates,
so it is unlikely that our findings were significantly different to
overall prescribing patterns in England.
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We based our assessment of ICS appropriateness on
spirometry in the previous two years. This reflects the evidence
base as all drug trials in COPD classify participants by
spirometry. Until trials of ICS in COPD are conducted using
broader assessment criteria, spirometry without exacerbation
history will remain the main arbiter of treatment suitability. We
did not collect data on pneumonia rates in COPD patients
because, despite the inherent inaccuracy of diagnosing
pneumonia without a chest x-ray which is rarely performed in
primary care, it was beyond the means of the study to estimate
the rate of occurrence of pneumonia in relation to duration of
exposure to combination inhalers.
Interpretation in relation to existing literature
A significant proportion of patients with a diagnosis of COPD
had not had their spirometric status confirmed and recorded. In
nearly a third that had had spirometry the record did not
support a diagnosis of COPD, comparable to findings in other
studies[1-3]. These diagnoses may have been made on the
basis of symptoms for which spirometry was not yet obtained,
or may have been the result of coding based on an incorrect
hospital discharge summary or radiology report. A number of
patients without spirometry confirmed COPD had a history of
hospital admissions or oral steroid prescription for COPD.
Some of this group may have had COPD but did not have
diagnostic confirmation due to poorly conducted spirometry, or
due to failure to attend for spirometry once the exacerbation
had resolved. Whilst the causes of this poor coding may be
multifactorial, there is on-going concern that a significant
proportion of patients are being prescribed high dose
treatments with potential side effects with no confirmed
diagnosis.
Over-prescribing of ICS in COPD has been reported in a
number of countries[1,2,32,33]. Factors underlying this may be
the perceived similarity of COPD and asthma, the common
occurrence of the two diseases together, and a hope that
steroids could reduce the impact of symptoms in COPD. ICS in
the low or moderate doses recommended in asthma, cause
few, mainly topical, side effects, so the potential benefits may
outweigh any disadvantages[34]. In COPD ICS are used in
higher doses with a corresponding increase in side effects.
Critical assessment of the risk/benefit ratio for an individual
patient would suggest targeting treatment at those with severe
disease and at greatest risk of frequent exacerbations.
We used the 2009 international GOLD guidelines to assess
treatment[26], which were consistent with the 2004 NICE
guidance current at the time of data collection. Since then
guidelines have diverged in their interpretation of the equivocal
data on benefits of ICS in reducing symptoms. GOLD still
defines the only indication for ICS use in COPD as the
prevention of exacerbations, though it now defines all patients
with severe/very severe COPD as being at risk. In contrast, the
updated UK NICE guideline in 2010 broadened the indication
for ICS in COPD to persistent breathlessness in mild and
moderate disease [18], a change likely to encourage yet more
prescribing of ICS. Unsurprisingly, it appears from this study
that primary care clinicians, faced with patients with on-going
symptoms will often err on the side of prescribing with the
attendant increased risks and escalating costs to health
services.
Conclusion
The majority of COPD patients in our study population were
treated appropriately according to international guidelines. A
significant proportion was over-treated with high-dose inhaled
corticosteroids – costly drugs that pose significant risks. The
situation is not helped when guidelines provide conflicting and
changing interpretations of equivocal data. A balanced
assessment (ideally from a source unaffected by conflicts of
interest) would help clinicians to weigh up the risks and
benefits of treatment for a progressive condition such as COPD
where treatment is often escalated in the hope of easing the
increasing burden of disease.
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